The Drug Enforcement Administration has proposed keeping its 2027 production quotas for Schedule I marijuana unchanged, while sharply raising quotas for several psychedelics. The proposal, filed for public inspection in the Federal Register on Nov. 9, 2026, also makes clear that quotas for marijuana already moved to Schedule III are still to come in a separate notice.
What the DEA proposed
The notice proposes 2027 aggregate production quotas (APQs) for Schedule I and II controlled substances. For marijuana still in Schedule I, which is produced for research, the DEA’s proposed table lists:
- Marijuana: 6,675,000 grams
- Marijuana extract: 1,000,000 grams
- Delta-9-THC: 1,523,040 grams
- All other THC: 1,166,130 grams
According to Marijuana Moment, these figures match the 2026 levels.
Psychedelic quotas rise
The same notice proposes the following 2027 quotas for psychedelics:
- Ibogaine: 12,002 grams (Marijuana Moment reports 210 grams for 2026)
- MDMA: 33,296 grams (reported 12,000 grams for 2026)
- Psilocybin: 60,000 grams (reported 50,000 grams)
- Psilocyn: 93,600 grams (reported 80,000 grams)
Marijuana Moment reports that the DEA says the increases align with executive orders from President Donald Trump, including one signed in April to speed legal access to psychedelics for patients with mental health conditions. Prior-year figures here come from that report and were not independently checked against last year’s notice.
Where Schedule III marijuana fits
This notice does not propose quotas for marijuana in Schedule III. The DEA says the table reflects only Schedule I marijuana, marijuana extract, and delta-9-THC, and that a separate Federal Register notice will propose quotas for the Schedule III substances once they are determined. The notice lists drug codes 7362, 7353, and 7386 as still under review. No date was given.
The DEA is also still registering the manufacturers and distributors that will handle Schedule III substances. Ganjly has covered that process in DEA’s first federal registrations for medical marijuana dispensaries. For the wider legal picture, see our rescheduling timeline tracker.
Why it matters
Quotas cap how much of a controlled substance can legally be manufactured in the United States. For Schedule I marijuana, that matters mainly for researchers. For Schedule III cannabis, the eventual quota will shape how much federally regulated product can enter the market. That figure is not yet proposed, so no forecast about supply is possible from this filing.
Marijuana Moment reports that the broader hearing on moving non-medical marijuana to Schedule III is still underway, and no decision date has been given. A quota notice for Schedule I does not change any marijuana’s legal status.
What happens next
After formal publication in the Federal Register, the DEA will accept public comments for 30 days. Marijuana Moment reported publication as scheduled for Wednesday, Nov. 11, while the notice’s placeholder dates point to a Nov. 10 publication and a Dec. 10 comment deadline (11:59 p.m. Eastern). Readers should confirm the final deadline on the published notice. Comments can be filed electronically or by mail postmarked by the deadline.
Sources
- DEA proposed aggregate production quotas notice, Federal Register public inspection document 2026-22843
- Marijuana Moment, Nov. 9, 2026
